Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels-Reference-Cited by-同舟云学术

Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels

Published:2019-10-08 Issue:2 Volume:121 Page:1736-1746
ISSN:0730-2312
Container-title:Journal of Cellular Biochemistry
language:en
Short-container-title:J Cell Biochem

Author:

Evans Mark Francis¹²^ORCID,Vacek Pamela Mary²³,Sprague Brian Lee²⁴,Stein Gary Stephen²⁵,Stein Janet Lee²⁵,Weaver Donald Lee¹²⁶

Affiliation:

1. Department of Pathology & Laboratory Medicine, Larner College of Medicine University of Vermont Burlington Vermont

2. University of Vermont Cancer Center, Larner College of Medicine, University of Vermont Burlington Vermont

3. Department of Medical Biostatistics, Larner College of Medicine University of Vermont Burlington Vermont

4. Department of Surgery, Larner College of Medicine University of Vermont Burlington Vermont

5. Department of Biochemistry, Larner College of Medicine University of Vermont Burlington Vermont

6. Department of Pathology & Laboratory Medicine University of Vermont Medical Center Burlington Vermont

Funder

Institut National Du Cancer

Publisher

Wiley

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcb.29409

Reference33 articles.

1. Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature

2. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

3. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

4. Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor–Positive Breast Cancer

5. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole brain alignment of spatial transcriptomics between humans and mice with BrainAlign;Nature Communications;2024-07-30

2. HOTAIR: a potential metastatic, drug-resistant and prognostic regulator of breast cancer;Molecular Cancer;2023-03-30

3. Identification of molecularly unique tumor-associated mesenchymal stromal cells in breast cancer patients;PLOS ONE;2023-03-20

4. Integrative, In Silico and Comparative Analysis of Breast Cancer Secretome Highlights Invasive-Ductal-Carcinoma-Grade Progression Biomarkers;Cancers;2022-08-09

5. Evaluation of the Suitability of RNAscope as a Technique to Measure Gene Expression in Clinical Diagnostics: A Systematic Review;Molecular Diagnosis & Therapy;2021-12-26